Positron Emission Tomography for neck evaluation following definitive treatment with chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma

Reviews on Recent Clinical Trials

Volumn 7, Issue 1, 2012, Pages 36-41

  Bar Ad, Voichita ^a   Mishra, Mark ^a   Ohri, Nitin ^a   Intenzo, Charles ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Head and Neck Cancer; Neck Dissection; Positron Emission Tomography

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER PATIENT; CHEMORADIOTHERAPY; EVALUATION; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84857400942     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488712799363226     Document Type: Review

References (48)

1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
2. Price P, Jones T. Can positron emission tomography be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31: 1924-1927.
3. Wahl RL, Hutchins GD, Buchsbaum DJ, et al. Fluorine-18-2-fluoro-2-deoxy-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 1991; 67: 1544-1550.
4. Gallagher BM, Fowler JS, Gutterson NF, MacGregor RR, Chung-Nan W, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-1161.
5. Pellitteri PK, Ferlito A, Fisher R, et al. Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all? Head Neck 2006; 28: 166-175.
6. Corry J, Peters L, Fisher R, et al. N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders-results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 2008; 30: 737-742.
7. Barkley HT Jr, Fletcher GH, Jesse RH, et al. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg 1972; 124: 462-467.
8. Mendenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the head and neck treated with radiation therapy: the role of neck dissection for clinically positive neck nodes. Int J Radiat Oncol Biol Phys 1986; 12: 733-740.
9. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharyngeal carcinoma. J Clin Oncol 2004; 22: 69-76.
10. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
11. Grabenbauer GG, Rodel C, Ernst-Stecken A, et al. Neck dissection following radiochemotherapy of advanced head and neck cancerfor selected cases only? Radiother Oncol 2003; 66: 57-63.
12. Argiris A, Stanson KM, Brockstein E, et al. Node dissection (ND) in the combined modality therapy of patients with locoregionally advanced head and neck cancer (HNC). Proc ASCO 2002; 21: 910.
13. Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in respectable stage III and IV squamous cell head and neck cancer. Head Neck 1997; 19: 559-566.
14. Lavertu P, Bonafede JP, Adelstein DJ, et al. Comparison of surgical complications after organ preservation therapy in patients with stage III and IV squamous cell head and neck cancer. Arch Otol Head Neck Surg 1998; 124: 401-406.
15. Davidson BJ, Newkirk KA, Harter KW, et al. Complications from planned post-treatment neck dissections. Arch Otol Head Neck Surg 1999; 125: 401-405.
16. Narayan K, Crane CH, Kleid S, Hughes PG, Peters LJ. Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck 1999; 21: 606-613.
17. Kuntz AL, Weymuller EA. Impact of neck dissection on quality of life. Laryngoscope 1999; 109: 1334-1338.
18. Ferlito A, Corry J, Silver CE, et al. Planned neck dissection for patients with complete response to chemoradiotherapy: A concept approach obsolescence. Head Neck 2010; 32: 253-261.
19. Strasser MD, Gleich LL, Miller MA, Saavedra HI, Gluckman JL. Management implications of evaluating the N2 and N3 neck after organ preservation therapy. Laryngoscope 1999; 109: 1776-1780.
20. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000; 126: 950-956.
21. Velazquez RA, McGuff HS, Sycamore D, Miller FR. The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiothereapy. Arch Otolaryngol Head Neck Surg 2004; 130: 74-77.
22. Liauw SL, Mancuso AA, Amdur RJ, et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer. The use of computed tomography to manage the neck. J Clin Oncol 2006; 24: 1421-1427.
23. Ojiri H, Mendenhall WM, Stringer SP, Johnson PL, Mancuso AA. Post-RT CT results as a predictive model for the necessity of planned post-RT neck dissection in patients with cervical metastatic disease from squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: 420-428.
24. Schoder H, Yeung HW, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004; 231: 65-72.
25. Branstetter BF, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235: 580-586.
26. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1315-1322.
27. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastases from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005; 63: 991-999.
28. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004; 60: 1410-1418.
29. Yao M, Graham MM, Hoffman HT, et al. The role of postradiation therapy FDG PET in prediction of necessity for postradiation therapy neck dissection in locally advanced head-andneck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 59: 1001-1010.
30. Tan A, Adelstein DJ, Rybickl LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck 2007; 133: 435-440.
31. McCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004; 26: 890-896.
32. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67 Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44: 198-206.
33. Hanasono MM, Kunda LD, Segall GM, et al. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-885.
34. Goguen LA, Posner MR, Tishler RB, et al. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg, 2006; 132: 526-531.
35. Brkovich VS, Miller FR, Karnad AB, et al. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope, 2006; 116: 855-858.
36. Ryan WR, Fee WE, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650.
37. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009; 74(1): 9-14.
38. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005; 27(3): 175-181.
39. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011 (in press).
40. Nayak JV, Walvekar R, Regiane SA, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: The utility of PET-CT. Laryngoscope 2007; 117: 2129-2134.
41. Ong SC, Schoder H, Lee NL, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540.
42. Gourin CG, Boyce BJ, Williams HT, et al. Revisiting the role of Positron-Emission Tomography/Computed Tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer. Laryngoscope 2009; 119: 2150-2155.
43. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009; 27: 2509-2515.
44. Gupta T, Jain S, Agarwal P, et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation. Radiother Oncol 2010; 97: 194-199.
45. Rabalais AG, Walvekar R, Nuss D, et al. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope 2009; 119: 1120-1124.
46. Gourin CG, Williams HT, Seabolt WN, Herdman AV, Hovington JW, Terris DJ. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngospcope 2006; 116: 705-710.
47. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33: 210-222.
48. Schoder H, Fury M, Lee N, Krauss D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50: 74S-88S.